{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T05:48:04Z","timestamp":1793512084255,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIHR Oxford Health BRC"},{"name":"Alexander Mosley Charitable Trust and by the founding partners of Imperial College London\u2019s Centre for Psychedelic Research."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent clinical trial data suggests that ratings on depression scales are lowered after psilocybin therapy compared to placebo, though it is unclear what neuropsychological mechanisms underpin these effects. This study compared psilocybin, with an established antidepressant, escitalopram, to investigate whether there are shared or distinct effects on emotional information processing. Patients with long-standing moderate-to-severe depression were randomly and double-blindly assigned in a 1:1 ratio to receive either 1) two doses of 25\u2009mg of psilocybin, 3-weeks apart, plus 6-weeks of daily placebo (psilocybin group N\u2009=\u200930); or 2) two doses of 1\u2009mg of psilocybin 3-weeks apart plus 6-weeks of daily oral escitalopram (escitalopram group N\u2009=\u200929); all patients received the same psychological support. Behavioural measures of affective bias as well as subjective measures of depression were collected at baseline and at the primary 6-week endpoint, using an established computerised task (Facial Emotion Recognition Task) and Quick Inventory of Depressive Symptomatology, respectively. Change in affective bias was further correlated with change in depression scores measured concurrently as well as at 1-month post-trial follow-up (week-10), corrected for baseline depression severity. Negative bias in facial expression recognition decreased after both treatments to a comparable level. Concurrently, change in negative affective bias was not associated with change in depression. Longitudinally, a decrease in the misclassification of positive faces as negative was associated with a decrease in depression scores at week-10 for the escitalopram group only. Therefore, a more positive behavioural bias in emotional processing was seen following psilocybin and citalopram compared to baseline. This highlights the potential for at least some overlap in cognitive mechanisms across two distinct treatments, which is noteworthy given the short dosing regimen with psilocybin.<\/jats:p>","DOI":"10.1038\/s41398-025-03693-w","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:55:41Z","timestamp":1763128541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Negative affective bias in depression following treatment with psilocybin or escitalopram \u2013 a secondary analysis from a randomized trial"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0108-1327","authenticated-orcid":false,"given":"Marieke A. G.","family":"Martens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Giribaldi","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-6211","authenticated-orcid":false,"given":"David","family":"Erritzoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-1401","authenticated-orcid":false,"given":"David","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carhart-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1609-8335","authenticated-orcid":false,"given":"Catherine J.","family":"Harmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"3693_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/2045125312445469","volume":"2","author":"E Penn","year":"2012","unstructured":"Penn E, Tracy DK. The drugs don\u2019t work? antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol. 2012;2:179\u201388.","journal-title":"Ther Adv Psychopharmacol"},{"key":"3693_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1176\/appi.focus.16407","volume":"16","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. FOC. 2018;16:420\u20139.","journal-title":"FOC"},{"key":"3693_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11920-022-01361-0","volume":"24","author":"D Prouzeau","year":"2022","unstructured":"Prouzeau D, Conejero I, Voyvodic PL, Becamel C, Abbar M, Lopez-Castroman J. Psilocybin efficacy and mechanisms of action in major depressive disorder: a Review. Curr Psychiatry Rep. 2022;24:573\u201381.","journal-title":"Curr Psychiatry Rep"},{"key":"3693_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264\u2013355.","journal-title":"Pharmacol Rev"},{"key":"3693_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Nutt DJ. Serotonin and brain function: a tale of two receptors. J Psychopharmacol. 2017;31:1091\u2013120.","journal-title":"J Psychopharmacol"},{"key":"3693_CR6","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenb\u00e6k DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacol. 2019;44:1328\u201334.","journal-title":"Neuropsychopharmacol"},{"key":"3693_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","volume":"181","author":"D Nutt","year":"2020","unstructured":"Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic psychiatry\u2019s brave new world. Cell. 2020;181:24\u20138.","journal-title":"Cell"},{"key":"3693_CR8","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","volume":"28","author":"RE Daws","year":"2022","unstructured":"Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022;28:844\u201351.","journal-title":"Nat Med"},{"key":"3693_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78:481\u20139.","journal-title":"JAMA Psychiatry"},{"key":"3693_CR10","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. New Engl J Med. 2021;384:1402\u201311.","journal-title":"New Engl J Med"},{"key":"3693_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/02698811231167848","volume":"37","author":"B Weiss","year":"2023","unstructured":"Weiss B, Erritzoe D, Giribaldi B, Nutt DJ, Carhart-Harris RL. A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression. J Psychopharmacol. 2023;37:717\u201332.","journal-title":"J Psychopharmacol"},{"key":"3693_CR12","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. New Engl J Med. 2022;387:1637\u201348.","journal-title":"New Engl J Med"},{"key":"3693_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330:843\u201353.","journal-title":"JAMA"},{"key":"3693_CR14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/02698811231154852","volume":"37","author":"J Sloshower","year":"2023","unstructured":"Sloshower J, Skosnik PD, Safi-Aghdam H, Pathania S, Syed S, Pittman B, et al. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. J Psychopharmacol. 2023;37:698\u2013706.","journal-title":"J Psychopharmacol"},{"key":"3693_CR15","doi-asserted-by":"publisher","first-page":"115531","DOI":"10.1016\/j.psychres.2023.115531","volume":"329","author":"S Haikazian","year":"2023","unstructured":"Haikazian S, Chen-Li DCJ, Johnson DE, Fancy F, Levinta A, Husain MI, et al. Psilocybin-assisted therapy for depression: a systematic review and meta-analysis. Psychiatry Res. 2023;329:115531.","journal-title":"Psychiatry Res"},{"key":"3693_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.euroneuro.2023.07.011","volume":"76","author":"N Perez","year":"2023","unstructured":"Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G, et al. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. Eur Neuropsychopharmacol. 2023;76:61\u201376.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3693_CR17","doi-asserted-by":"publisher","first-page":"e078084","DOI":"10.1136\/bmj-2023-078084","volume":"385","author":"AM Metaxa","year":"2024","unstructured":"Metaxa AM, Clarke M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024;385:e078084.","journal-title":"BMJ"},{"key":"3693_CR18","doi-asserted-by":"publisher","unstructured":"Aghajanian S, Shafiee A, Parvizi Omran S, Rezaei Nejad A, Jafarabady K, Kohandel Gargari O, et al. Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials. J Psychopharmacol. 2024;https:\/\/doi.org\/10.1177\/02698811241287542.","DOI":"10.1177\/02698811241287542"},{"key":"3693_CR19","doi-asserted-by":"publisher","first-page":"20120407","DOI":"10.1098\/rstb.2012.0407","volume":"368","author":"CJ Harmer","year":"2013","unstructured":"Harmer CJ, Cowen PJ. It\u2019s the way that you look at it\u2019\u2014a cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc Lond B Biol Sci. 2013;368:20120407.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"3693_CR20","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1177\/0269881117739552","volume":"31","author":"NT Huneke","year":"2017","unstructured":"Huneke NT, Walsh AE, Brown R, Browning M, Harmer CJ. No evidence for an acute placebo effect on emotional processing in healthy volunteers. J Psychopharmacol. 2017;31:1578\u201387.","journal-title":"J Psychopharmacol"},{"key":"3693_CR21","doi-asserted-by":"publisher","first-page":"12107","DOI":"10.1038\/s41598-023-34938-7","volume":"13","author":"B Szigeti","year":"2023","unstructured":"Szigeti B, Nutt D, Carhart-Harris R, Erritzoe D. The difference between \u2018placebo group\u2019 and \u2018placebo control\u2019: a case study in psychedelic microdosing. Sci Rep. 2023;13:12107","journal-title":"Sci Rep"},{"key":"3693_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/02698811231180276","volume":"37","author":"OR Hovmand","year":"2023","unstructured":"Hovmand OR, Poulsen ED, Arnfred S, Storeb\u00f8 OJ. Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review. J Psychopharmacol. 2023;37:649\u201359.","journal-title":"J Psychopharmacol"},{"key":"3693_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114297","volume":"307","author":"AJ Scott","year":"2022","unstructured":"Scott AJ, Sharpe L, Colagiuri B. A systematic review and meta-analysis of the success of blinding in antidepressant RCTs. Psychiatry Res. 2022;307:114297.","journal-title":"Psychiatry Res"},{"key":"3693_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00213-019-05448-0","volume":"238","author":"BR Godlewska","year":"2021","unstructured":"Godlewska BR, Harmer CJ. Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment. Psychopharmacology (Berl). 2021;238:1265\u201378.","journal-title":"Psychopharmacology (Berl)"},{"key":"3693_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev.ps.45.020194.000325","volume":"45","author":"A Mathews","year":"1994","unstructured":"Mathews A, MacLeod C. Cognitive approaches to emotion and emotional disorders. Annu Rev Psychol. 1994;45:25\u201350.","journal-title":"Annu Rev Psychol"},{"key":"3693_CR26","doi-asserted-by":"publisher","unstructured":"Robinson ESJ, Roiser JP. Affective biases in humans and animals. In: Robbins TW, Sahakian BJ, editors. Translational Neuropsychopharmacology [Internet]. Cham: Springer International Publishing; 2016 [cited 2021 Nov 15]. p. 263\u201386. (Current Topics in Behavioral Neurosciences). Available from: https:\/\/doi.org\/10.1007\/7854_2015_5011","DOI":"10.1007\/7854_2015_5011"},{"key":"3693_CR27","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1176\/appi.ajp.2009.09020149","volume":"166","author":"Harmer","year":"2009","unstructured":"Harmer, O\u2019Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. AJP. 2009;166:1178\u201384.","journal-title":"AJP"},{"key":"3693_CR28","unstructured":"Beck AT. Cognitive therapy of depression. Guilford press; 1979."},{"key":"3693_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrn3027","volume":"12","author":"SG Disner","year":"2011","unstructured":"Disner SG, Beevers CG, Haigh EAP, Beck AT. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci. 2011;12:467\u201377.","journal-title":"Nat Rev Neurosci"},{"key":"3693_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1192\/bjp.bp.108.051193","volume":"195","author":"Harmer","year":"2009","unstructured":"Harmer, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009;195:102\u20138.","journal-title":"Br J Psychiatry"},{"key":"3693_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jad.2009.01.028","volume":"118","author":"R Tranter","year":"2009","unstructured":"Tranter R, Bell D, Gutting P, Harmer C, Healy D, Anderson IM. The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. J Affect Disord. 2009;118:87\u201393.","journal-title":"J Affect Disord"},{"key":"3693_CR32","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/gps.4104","volume":"29","author":"PR Shiroma","year":"2014","unstructured":"Shiroma PR, Thuras P, Johns B, Lim KO. Emotion recognition processing as early predictor of response to 8-week citalopram treatment in late-life depression. Int J Geriatr Psychiatry. 2014;29:1132\u20139.","journal-title":"Int J Geriatr Psychiatry"},{"key":"3693_CR33","doi-asserted-by":"publisher","first-page":"e957","DOI":"10.1038\/tp.2016.130","volume":"6","author":"BR Godlewska","year":"2016","unstructured":"Godlewska BR, Browning M, Norbury R, Cowen PJ, Harmer CJ. Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression. Transl Psychiatry. 2016;6:e957\u2013e957.","journal-title":"Transl Psychiatry"},{"key":"3693_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.euroneuro.2018.11.1102","volume":"29","author":"M Browning","year":"2019","unstructured":"Browning M, Kingslake J, Dourish CT, Goodwin GM, Harmer CJ, Dawson GR. Predicting treatment response to antidepressant medication using early changes in emotional processing. Eur Neuropsychopharmacol. 2019;29:66\u201375.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3693_CR35","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/s41386-021-00981-z","volume":"46","author":"M Browning","year":"2021","unstructured":"Browning M, Bilderbeck AC, Dias R, Dourish CT, Kingslake J, Deckert J, et al. The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trial. Neuropsychopharmacol. 2021;46:1307\u201314.","journal-title":"Neuropsychopharmacol"},{"key":"3693_CR36","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/npp.2015.348","volume":"41","author":"A Post","year":"2016","unstructured":"Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, et al. A selective nociceptin receptor antagonist to treat depression: evidence from preclinical and clinical studies. Neuropsychopharmacol. 2016;41:1803\u201312.","journal-title":"Neuropsychopharmacol"},{"key":"3693_CR37","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1080\/02699931.2015.1055713","volume":"30","author":"T Adams","year":"2016","unstructured":"Adams T, Pounder Z, Preston S, Hanson A, Gallagher P, Harmer CJ, et al. Test\u2013retest reliability and task order effects of emotional cognitive tests in healthy subjects. Cognition Emot. 2016;30:1247\u201359.","journal-title":"Cognition Emot"},{"key":"3693_CR38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1176\/appi.ajp.20230751","volume":"182","author":"MB Wall","year":"2025","unstructured":"Wall MB, Demetriou L, Giribaldi B, Roseman L, Ertl N, Erritzoe D, et al. Reduced brain responsiveness to emotional stimuli with escitalopram but not psilocybin therapy for depression. AJP. 2025;182:569\u201382.","journal-title":"AJP"},{"key":"3693_CR39","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3390\/ph14080800","volume":"14","author":"MAG Martens","year":"2021","unstructured":"Martens MAG, Kaltenboeck A, Halahakoon DC, Browning M, Cowen PJ, Harmer CJ. An experimental medicine investigation of the effects of subacute pramipexole treatment on emotional information processing in healthy volunteers. Pharmaceuticals. 2021;14:800.","journal-title":"Pharmaceuticals"},{"key":"3693_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0010-0277(97)00003-6","volume":"63","author":"AW Young","year":"1997","unstructured":"Young AW, Rowland D, Calder AJ, Etcoff NL, Seth A, Perrett DI. Facial expression megamix: tests of dimensional and category accounts of emotion recognition. Cognition. 1997;63:271\u2013313.","journal-title":"Cognition"},{"key":"3693_CR41","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1037\/h0031246","volume":"75","author":"JB Grier","year":"1971","unstructured":"Grier JB. Nonparametric indexes for sensitivity and bias: computing formulas. Psychol Bull. 1971;75:424.","journal-title":"Psychol Bull"},{"key":"3693_CR42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/psymed.2022.0002","volume":"1","author":"SM Nayak","year":"2023","unstructured":"Nayak SM, Bari BA, Yaden DB, Spriggs MJ, Rosas FE, Peill JM, et al. A bayesian reanalysis of a trial of psilocybin versus escitalopram for depression. Psychedelic Med. 2023;1:18\u201326.","journal-title":"Psychedelic Med"},{"key":"3693_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-021-01706-y","volume":"11","author":"MK Doss","year":"2021","unstructured":"Doss MK, Pova\u017ean M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 2021;11:1\u201310.","journal-title":"Transl Psychiatry"},{"key":"3693_CR44","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00213-017-4754-y","volume":"235","author":"JB Stroud","year":"2018","unstructured":"Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, et al. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology (Berl). 2018;235:459\u201366.","journal-title":"Psychopharmacology (Berl)"},{"key":"3693_CR45","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","volume":"72","author":"M Kometer","year":"2012","unstructured":"Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 2012;72:898\u2013906.","journal-title":"Biol Psychiatry"},{"key":"3693_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00213-012-2811-0","volume":"225","author":"A Schmidt","year":"2013","unstructured":"Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider F. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology (Berl). 2013;225:227\u201339.","journal-title":"Psychopharmacology (Berl)"},{"key":"3693_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/02698811211026454","volume":"36","author":"DEW McCulloch","year":"2022","unstructured":"McCulloch DEW, Madsen MK, Stenb\u00e6k DS, Kristiansen S, Ozenne B, Jensen PS, et al. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. J Psychopharmacol. 2022;36:74\u201384.","journal-title":"J Psychopharmacol"},{"key":"3693_CR48","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1093\/cercor\/bht178","volume":"24","author":"F Bernasconi","year":"2014","unstructured":"Bernasconi F, Schmidt A, Pokorny T, Kometer M, Seifritz E, Vollenweider FX. Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A\/2A receptor agonist psilocybin. Cereb Cortex. 2014;24:3221\u201331.","journal-title":"Cereb Cortex"},{"key":"3693_CR49","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","volume":"78","author":"R Kraehenmann","year":"2015","unstructured":"Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2015;78:572\u201381.","journal-title":"Biol Psychiatry"},{"key":"3693_CR50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nicl.2015.08.009","volume":"11","author":"R Kraehenmann","year":"2016","unstructured":"Kraehenmann R, Schmidt A, Friston K, Preller KH, Seifritz E, Vollenweider FX. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage: Clin. 2016;11:53\u201360.","journal-title":"NeuroImage: Clin"},{"key":"3693_CR51","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.euroneuro.2018.03.016","volume":"28","author":"O Grimm","year":"2018","unstructured":"Grimm O, Kraehenmann R, Preller KH, Seifritz E, Vollenweider FX. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. Eur Neuropsychopharmacol. 2018;28:691\u2013700.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3693_CR52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","volume":"142","author":"L Roseman","year":"2018","unstructured":"Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology. 2018;142:263\u20139.","journal-title":"Neuropharmacology"},{"key":"3693_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59282-y","volume":"10","author":"FS Barrett","year":"2020","unstructured":"Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10:2214.","journal-title":"Sci Rep"},{"key":"3693_CR54","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0269881119895520","volume":"34","author":"LJ Mertens","year":"2020","unstructured":"Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol. 2020;34:167\u201380.","journal-title":"J Psychopharmacol"},{"key":"3693_CR55","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings Natl Acad Sci. 2012;109:2138\u201343.","journal-title":"Proceedings Natl Acad Sci"},{"key":"3693_CR56","doi-asserted-by":"publisher","unstructured":"Carhart-Harris R, Leech R, Hellyer P, Shanahan M, Feilding A, Tagliazucchi E, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience [Internet]. 2014;8 https:\/\/doi.org\/10.3389\/fnhum.2014.000208. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fnhum.2014.00020.","DOI":"10.3389\/fnhum.2014.000208"},{"key":"3693_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13282-7","volume":"7","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7:13187.","journal-title":"Sci Rep"},{"key":"3693_CR58","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","volume":"45","author":"NL Mason","year":"2020","unstructured":"Mason NL, Kuypers KPC, M\u00fcller F, Reckweg J, Tse DHY, Toennes SW, et al. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacol. 2020;45:2003\u201311.","journal-title":"Neuropsychopharmacol"},{"key":"3693_CR59","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.biopsych.2019.12.027","volume":"88","author":"KH Preller","year":"2020","unstructured":"Preller KH, Duerler P, Burt JB, Ji JL, Adkinson B, St\u00e4mpfli P, et al. Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry. 2020;88:197\u2013207.","journal-title":"Biol Psychiatry"},{"key":"3693_CR60","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cub.2016.02.010","volume":"26","author":"E Tagliazucchi","year":"2016","unstructured":"Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, et al. Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol. 2016;26:1043\u201350.","journal-title":"Curr Biol"},{"key":"3693_CR61","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression. Journal Humanist Psychol. 2017;57:520\u201364.","journal-title":"Journal Humanist Psychol"},{"key":"3693_CR62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1503\/jpn.110005","volume":"37","author":"C Lord","year":"2012","unstructured":"Lord C, Steiner M, Soares C, Carew C, Hall G. Stress response in postpartum women with and without obsessive\u2013compulsive symptoms: an fMRI study. Journal Psychiatry Neurosci. 2012;37:78\u201386.","journal-title":"Journal Psychiatry Neurosci"},{"key":"3693_CR63","doi-asserted-by":"publisher","first-page":"239821282110077","DOI":"10.1177\/23982128211007772","volume":"5","author":"J Haarsma","year":"2021","unstructured":"Haarsma J, Harmer CJ, Tamm S. A continuum hypothesis of psychotomimetic rapid antidepressants. Brain Neurosci Adv. 2021;5:23982128211007772.","journal-title":"Brain Neurosci Adv"},{"key":"3693_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi2403","volume":"16","author":"JK Hinchcliffe","year":"2024","unstructured":"Hinchcliffe JK, Stuart SA, Wood CM, Bartlett J, Kamenish K, Arban R, et al. Rapid-acting antidepressant drugs modulate affective bias in rats. Science Transl Med. 2024;16:eadi2403.","journal-title":"Science Transl Med"},{"key":"3693_CR65","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","volume":"25","author":"AC Kwan","year":"2022","unstructured":"Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci. 2022;25:1407\u201319.","journal-title":"Nat Neurosci"},{"key":"3693_CR66","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1017\/S0033291723003653","volume":"54","author":"B Szigeti","year":"2024","unstructured":"Szigeti B, Weiss B, Rosas FE, Erritzoe D, Nutt D, Carhart-Harris R. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychol Med. 2024;54:1717\u201324.","journal-title":"Psychol Med"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03693-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03693-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03693-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T02:01:55Z","timestamp":1764036115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03693-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3693"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03693-w","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DE reports to have received scientific consultancy fees from Aya Biosciences, Lophora Aps, Clerkenwell Health, and Mindstate Design Lab. DJN has received lecture fees from Lundbeck Otsuka Takeda and Janssen. RCH reports receiving consulting fees from MindState, Entheos Lab and Tryp Therapeutics. Also note for DJN and RCH: the Imperial College psychedelic centre has received support from the following companies developing psychedelic therapy for depression: COMPASSPathways, Usona, Small Pharma, Beckley Psytec. CJH has received consultancy fees from P1vital Ltd., Janssen Pharmaceuticals, Sage Therapeutics, Pfizer, Zogenix, Compass Pathways, and Lundbeck. Prof. Harmer has held grant income from Zogenix, UCB Pharma, Janssen Pharmaceuticals. BG received consulting fees from SmallPharma. MM declares that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"502"}}